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ABSTRACT:  We conducted genome-wide association studies of three phenotypes: subjective well-
being (SWB; N = 298,420), depressive symptoms (DS; N = 161,460), and neuroticism (N = 170,910). 
We identified three variants associated with SWB, two with DS, and eleven with neuroticism, 
including two inversion polymorphisms. The two DS loci replicate in an independent depression 
sample. Joint analyses that exploit the high genetic correlations between the phenotypes (|࣋ෝ| ൎ ૙. ૡ) 
strengthen the overall credibility of the findings, and allow us to identify additional variants. Across 
our phenotypes, loci regulating expression in central nervous system and adrenal/pancreas tissues are 
strongly enriched for association. 
Subjective well-being (SWB)—as measured by survey questions on life satisfaction, positive affect, or 
happiness—is a major topic of research within psychology, economics, and epidemiology. Twin studies 
have found that SWB is genetically correlated with depression (characterized by negative affect, anxiety, 
low energy, bodily aches and pains, pessimism, and other symptoms) and neuroticism (a personality trait 
characterized by easily experiencing negative emotions such as anxiety and fear)1–3. Depression and 
neuroticism have received much more attention than SWB in genetic-association studies, but the discovery 
of associated genetic variants with either of them has proven elusive4,5. 
In this paper, we report a series of separate and joint analyses of SWB, depressive symptoms (DS), and 
neuroticism. Our primary analysis is a genome-wide association study (GWAS) of SWB based on data from 
59 cohorts (N = 298,420). This GWAS identifies three loci associated with SWB at genome-wide 
significance (p < 5×10-8). We supplement this primary analysis with auxiliary GWAS meta-analyses of DS 
(N = 180,866) and neuroticism (N = 170,910), performed by combining publicly available summary 
statistics from published studies with new genome-wide analyses of additional data. In these auxiliary 
analyses we identify two loci associated with DS and eleven with neuroticism, including two inversion 
polymorphisms. In depression data from an independent sample (N = 368,890), both DS associations 
replicate (p = 0.004 and p = 0.015). 
In our two joint analyses, we exploit the high genetic correlation between SWB, DS, and neuroticism (i) to 
evaluate the credibility of the 16 genome-wide significant associations across the three phenotypes, and (ii) 
to identify novel associations (beyond those identified by the GWAS). For (i), we investigate whether our 
three SWB-associated SNPs “quasi-replicate” by testing them for association with DS and neuroticism. We 
similarly examine the quasi-replication record of the DS and neuroticism loci by testing them for association 
with SWB. We find that the quasi-replication record closely matches what would be expected given our 
statistical power if none of the genome-wide significant associations were chance findings. These results 
strengthen the credibility of (most of) the original associations. For (ii), we use a “proxy phenotype” 
approach6: we treat the set of loci associated with SWB at p < 10-4 as candidates, and we test them for 
association with DS and neuroticism. At the Bonferroni-adjusted 0.05 significance threshold, we identify 
two loci associated with both DS and neuroticism and another two associated with neuroticism. 
In designing our study, we faced a tradeoff between analyzing a smaller sample with a homogeneous 
phenotype measure versus attaining a larger sample by jointly analyzing data from multiple cohorts with 
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heterogeneous measures. For example, in our analysis of SWB, we include measures of both life satisfaction 
(LS) and positive affect (PA), even though these constructs are conceptually distinct7. In Supplementary 
Note, we present a theoretical framework for evaluating the costs and benefits of pooling heterogeneous 
measures. In our context, given the high genetic correlation across measures, the framework predicts that 
pooling increases statistical power to detect variants. This prediction is supported by our results. 
RESULTS 
GWAS of SWB 
Following a pre-specified analysis plan, we conducted a sample-size-weighted meta-analysis (N = 298,420) 
of cohort-level GWAS summary statistics. The phenotype measure was LS, PA, or (in some cohorts) a 
measure combining LS and PA. We confirmed previous findings9 of high pairwise genetic correlation 
between LS and PA using bivariate LD Score regression10 (ߩො = 0.981 (SE = 0.065); Supplementary Table 
1). Details on the 59 participating cohorts, their phenotype measures, genotyping, quality-control filters, and 
association models are provided in Online Methods, Supplementary Note, and Supplementary Tables 2-6. 
As expected under polygenicity11, we observe inflation of the median test statistic (λGC = 1.206). The 
estimated intercept from LD Score regression (1.012) suggests that nearly all of the inflation is due to 
polygenic signal rather than bias. We also performed family-based analyses that similarly suggest minimal 
confounding due to population stratification (Online Methods). Using a clumping procedure (Online 
Methods), we identified three approximately independent SNPs reaching genome-wide significance (“lead 
SNPs”). These three lead SNPs are indicated in the Manhattan plot (Figure 1a) and listed in Table 1. The 
SNPs have estimated effects in the range 0.015 to 0.018 standard deviations (SDs) per allele (each R2	ൎ
	0.01%). 
We also conducted separate meta-analyses of the components of our SWB measure, LS (N = 166,205) and 
PA (N = 180,281) (Online Methods). Consistent with our theoretical conclusion that pooling heterogeneous 
measures increased power in our context, the LS and PA analyses yielded fewer signals across a range of p-
value thresholds than our meta-analysis of SWB (Supplementary Table 7). 
GWAS of DS and neuroticism 
We conducted auxiliary GWAS of DS and neuroticism (see Online Methods, Supplementary Note, and 
Supplementary Tables 8-12 for details on cohorts, phenotype measures, genotyping, association models, 
and quality-control filters). For DS (N = 180,866), we meta-analyzed publicly available results from a study 
performed by the Psychiatric Genomics Consortium (PGC)12 together with new results from analyses of the 
initial release of the UK Biobank data (UKB)13 and the Resource for Genetic Epidemiology Research on 
Aging (GERA) Cohort14. In UKB (N = 105,739), we constructed a continuous phenotype measure by 
combining responses to two questions, which ask about the frequency with which the respondent 
experienced feelings of unenthusiasm/disinterest or unenthusiasm/disinterest in the past two weeks. The 
other cohorts had ascertained case-control data on major depressive disorder (GERA: Ncases = 7,231, Ncontrols 
= 49,316; PGC: Ncases = 9,240, Ncontrols = 9,519). 
For neuroticism (N = 170,910), we pooled summary statistics from a published study by the Genetics of 
Personality Consortium (GPC)4 with results from a new analysis of UKB data. The GPC (N = 63,661) 
harmonized different neuroticism batteries. In UKB (N = 107,245), our measure was the respondent’s score 
on a 12-item version of the Eysenck Personality Inventory Neuroticism scale15. 
In both the DS and neuroticism GWAS, the heterogeneous phenotypic measures are highly genetically 
correlated (Supplementary Table 1). As in our SWB analyses, there is substantial inflation of the median 
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test statistics (λGC = 1.168 for DS, λGC = 1.317 for neuroticism), but the estimated LD Score intercepts (1.008 
and 0.998, respectively) suggest that bias accounts for little or none of the inflation. 
For DS, we identified two lead SNPs, indicated in the Manhattan plot (Fig. 1b). For neuroticism, our meta-
analysis yielded 16 loci that are independent according to our locus definition (Fig. 1c). However, 6 of these 
reside within a well-known inversion polymorphism on chromosome 816. We established that all genome-
wide significant signals in the inversion region are attributable to the inversion, and we confirmed that the 
inversion is associated with neuroticism in both of our neuroticism datasets, the GPC and the UKB (Online 
Methods and Supplementary Note). In our list of lead SNPs (Table 1), we only retain the most strongly 
associated SNP from these 6 loci to tag the chromosome 8 inversion. 
Another lead SNP associated with neuroticism, rs193236081, is located within a well-known inversion 
polymorphism on chromosome 17. We established that this association is attributable to the inversion 
polymorphism (Online Methods and Supplementary Note). Because this inversion yields only one 
significant locus and is genetically complex17, we hereafter simply use its lead SNP as its proxy. Our 
neuroticism GWAS therefore identified 11 lead SNPs, two of which tag inversion polymorphisms. A 
concurrent, unpublished neuroticism GWAS using a subset of our sample reports similar findings18. 
As shown in Table 1, the estimated effects of all lead SNPs associated with DS and neuroticism are in the 
range 0.020 to 0.031 SDs per allele (R2 ൎ 0.02% to 0.04%). In the UKB cohort we estimated the effect of an 
additional allele of the chromosome 8 inversion polymorphism itself on neuroticism to be 0.035 SDs 
(Supplementary Table 13). 
Genetic overlap across SWB, DS, and neuroticism 
Figure 2a shows that the three pairwise genetic correlations between our phenotypes, estimated using 
bivariate LD Score regression10, are substantial: -0.81 (SE = 0.046) between SWB and DS, -0.75 (SE = 
0.034) between SWB and neuroticism, and 0.75 (SE = 0.027) between DS and neuroticism. Using height as 
a negative control, we also examined pairwise genetic correlations between each of our phenotypes and 
height and, as expected, found all three to be modest, e.g., 0.07 with SWB (Supplementary Table 1). The 
high genetic correlations between SWB, DS, and neuroticism may suggest that the genetic influences on 
these phenotypes are predominantly related to processes common across the phenotypes, such as mood, 
rather than being phenotype-specific. 
Quasi-replication and Bayesian credibility analyses 
We assessed the credibility of our findings using a standard Bayesian framework19,20 in which a positive 
fraction of SNPs have null effects and a positive fraction have non-null effects (Online Methods). For each 
phenotype, the non-null effect sizes are assumed to be drawn from a normal distribution whose variance is 
estimated from the GWAS summary statistics. As a first analysis, for each lead SNP’s association with its 
phenotype, we calculated the posterior probability of null association after having observed the GWAS 
results. We found that, for any assumption about the fraction of non-null SNPs in the range 1% to 99%, the 
probability of true association always exceeds 95% for all 16 loci (and always exceeds 98% for 14 of them). 
To further probe the credibility of the findings, we performed “quasi-replication” exercises (Online 
Methods) in which we tested the SWB lead-SNPs for association with DS and neuroticism. We similarly 
tested the DS lead-SNPs and the neuroticism lead-SNPs for association with SWB. Below, we refer to the 
phenotype for which the lead SNP was identified as the first-stage phenotype and the phenotype used for the 
quasi-replication as the second-stage phenotype. To avoid sample overlap, for each quasi-replication 
analysis we omitted any cohorts that contributed to the GWAS of the first-stage phenotype. 
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Results of the quasi-replication of the three SWB lead-SNPs are shown in Figure 3a. For ease of 
interpretation, the reference allele for each association in the figure is chosen such that the predicted sign of 
the second-stage estimate is positive. We find that two out of the three SWB lead-SNPs are significantly 
associated with DS (p = 0.004 and p = 0.001) in the predicted direction. For neuroticism, where the second-
stage sample size (N = 68,201) is about half as large, the SWB-increasing allele has the predicted sign for all 
three SNPs, but none reach significance. 
Figures 3b and 3c show the results for the DS and neuroticism lead-SNPs, respectively. In each panel, the 
blue crosses depict results from the quasi-replications where SWB is the second-stage phenotype. We find 
that the two DS lead-SNPs have the predicted sign for SWB, and one is nominally significant (p = 0.04). 
Finally, of the eleven neuroticism lead-SNPs, nine have the predicted sign for SWB. Four of the eleven are 
nominally significantly associated with SWB, all with the predicted sign. One of the four is the SNP tagging 
the inversion on chromosome 816. That SNP’s association with neuroticism (and likely with SWB) is driven 
by its correlation with the inversion (Supplementary Fig. 1). 
To evaluate what these quasi-replication results imply about the credibility of the 16 GWAS associations, 
we compared the observed quasi-replication record to the quasi-replication record expected given our 
statistical power. We calculated statistical power using our Bayesian framework, under the hypothesis that 
each lead SNP has a non-null effect on both the first- and second-stage phenotypes. Our calculations take 
into account both the imperfect genetic correlation between the first- and second-stage phenotypes and 
inflation of the first-stage estimates due to the well-known problem of winner’s curse (Online Methods). Of 
the 19 quasi-replication tests, our calculations imply that 16.7 would be expected to yield the anticipated 
sign and 6.9 would be significant at the 5% level. The observed numbers are 16 and 7. Our quasi-replication 
results are thus consistent with the hypothesis that none of the 16 genome-wide significant associations are 
chance findings, and in fact strengthen the credibility of our GWAS results (Supplementary Table 14). 
Lookup of DS and neuroticism lead-SNPs  
Investigators of an ongoing large-scale GWAS of major depressive disorder (N = 368,890) in the 23andMe 
cohort shared association results for the loci identified in our DS and neuroticism analyses (Online Methods 
and Supplementary Table 15)21. Because the depression sample overlaps with our SWB sample, we did not 
request a lookup of the SWB-associated SNPs.  
In Figures 3b and 3c, the results are depicted as green crosses. For interpretational ease, we chose the 
reference allele so that positive coefficients imply that the estimated effect is in the predicted direction. All 
13 associations have the predicted sign. Of the 11 neuroticism polymorphisms, four are significantly 
associated with depression at the 5% level. Both of the DS lead-SNPs replicate (p = 0.004 and p = 0.015), 
with effect sizes (0.007 and -0.006 SDs per allele) strikingly close to those predicted by our Bayesian 
framework (0.008 and -0.006) (Supplementary Table 14 and Supplementary Table 15). 
Panel A of Table 1 summarizes the results for the 16 lead SNPs identified across our separate GWA 
analyses of the three phenotypes. The right-most column summarizes the statistical significance of the quasi-
replication and depression lookup analyses of each SNP. 
Proxy-phenotype analyses 
To identify additional SNPs associated with DS, we conducted a two-stage “proxy phenotype” analysis 
(Online Methods). In the first stage, we ran a new GWAS of SWB to identify a set of candidate SNPs. 
Specifically, from each locus exhibiting suggestive evidence of association (p < 10-4) with SWB, we 
retained the SNP with the lowest p-value as a candidate. In the second stage, we tested these candidates for 
association with DS at the 5% significance threshold, Bonferroni-adjusted for the number of candidates. We 
used an analogous two-stage procedure to identify additional SNPs associated with neuroticism. The first-
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stage SWB sample differs across the two proxy-phenotype analyses (and from the primary SWB GWAS 
sample) because we assigned cohorts across the first and second stages so as to maximize statistical power 
for the overall procedure. 
For DS, there are 163 candidate SNPs. 115 of them (71%) have the predicted direction of effect on DS, 20 
are significantly associated at the 5% significance level (19 in the predicted direction), and two remain 
significant after Bonferroni adjustment. For neuroticism, there are 170 candidate SNPs. 129 of them (76%) 
have the predicted direction of effect, all 28 SNPs significant at the 5% level have the predicted sign, and 
four of these remain significant after Bonferroni adjustment (Supplementary Fig. 2 and Supplementary 
Tables 16 and 17). Two of the four are the SNPs identified in the proxy-phenotype analysis for DS.  
Table 1 lists the four SNPs in total identified by the proxy-phenotype analyses. 
Biological analyses 
To shed some light on possible biological mechanisms underlying our findings, we conducted several 
analyses. 
We began by using bivariate LD Score regression10 to quantify the amount of genetic overlap between each 
of our three phenotypes and ten neuropsychiatric and physical health. Figures 2b and c display the estimates 
for SWB and the negative of the estimates for DS and neuroticism (since SWB is negatively genetically 
correlated with DS and neuroticism). SWB, DS, and neuroticism have strikingly similar patterns of pairwise 
genetic correlation with the other phenotypes. 
Figure 2b shows the results for the five neuropsychiatric phenotypes we examined: Alzheimer’s disease, 
anxiety disorders, autism spectrum disorder, bipolar disorder, and schizophrenia. For four of these 
phenotypes, genetic correlations with depression (but not neuroticism or SWB) were reported in Bulik-
Sullivan et al.10. For schizophrenia and bipolar disorder, our estimated correlations with DS, 0.33 and 0.26, 
are substantially lower than Bulik-Sullivan et al.’s point estimates but contained within their 95% 
confidence intervals. By far the largest genetic correlations we estimate are with anxiety disorders: −0.73 
with SWB, 0.88 with DS, and 0.86 with neuroticism. Genetic correlations estimated from GWAS data have 
not been previously reported for anxiety disorders. 
Figure 2c shows the results for five physical health phenotypes that are known or believed to be risk factors 
for various adverse health outcomes: body mass index (BMI), ever-smoker status, coronary artery disease, 
fasting glucose, and triglycerides. The estimated genetic correlations are all small in magnitude, consistent 
with earlier work, although the greater precision of our estimates allows us to reject null effects in most 
cases. The signs are generally consistent with those of the phenotypic correlations reported in earlier work 
between our phenotypes and outcomes such as obesity22, smoking23,24, and cardiovascular health25. 
Next, to investigate whether our GWAS results are enriched in particular functional categories, we applied 
stratified LD Score regression26 to our meta-analysis results. In our first analysis, we report estimates for all 
53 functional categories included in the “baseline model”; the results for SWB, DS, and neuroticism are 
broadly similar (Supplementary Tables 18-20) and are in line with what has been found for other 
phenotypes26. In our second analysis, the categories are groupings of SNPs likely to regulate gene 
expression in cells of a specific tissue. The estimates for SWB, DS, and neuroticism are shown in Figure 4a, 
alongside height, which is again included as a benchmark27 (see also Supplementary Table 21). 
We found significant enrichment of CENTRAL NERVOUS SYSTEM for all three phenotypes and, perhaps more 
surprisingly, enrichment of ADRENAL/PANCREAS for SWB and DS. The cause of the ADRENAL/PANCREAS 
enrichment is unclear, but we note that the adrenal glands produce several hormones, including cortisol, 
epinephrine, and norepinephrine, known to play important roles in the bodily regulation of mood and stress. 
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It has been robustly found that blood serum levels of cortisol in patients afflicted by depression are elevated 
relative to controls28.  
While the above analyses utilize the genome-wide data, we also conducted three analyses (Online Methods) 
restricted to the 16 GWAS and four proxy-phenotype SNPs in Table 1. In brief, we ascertained whether 
each SNP (or a variant in strong linkage disequilibrium (LD) with it) falls into any of the following three 
classes: (i) resides in a locus for which genome-wide significant associations with other phenotypes have 
been reported (Supplementary Table 22), (ii) is nonsynonymous (Supplementary Table 23), and (iii) is an 
eQTL in blood or in one of 14 other tissues (although the non-blood analyses are based on smaller samples) 
(Supplementary Table 24). Here we highlight a few particularly interesting results. 
We found that five of the 20 SNPs are in loci in which genome-wide significant associations have 
previously been reported. Two of these five are schizophrenia loci. Interestingly, one of them harbors the 
gene DRD2, which encodes the D2 subtype of the dopamine receptor, a target for antipsychotic drugs29 that 
is also known to play a key role in neural reward pathways30. Motivated by these findings, as well as by the 
modest genetic correlations with schizophrenia reported in Figure 2b, we examined whether the SNPs 
identified in a recent study of schizophrenia31 are enriched for association with neuroticism in our non-
overlapping UKB sample (N = 107,245). We conducted several tests and found strong evidence of such 
enrichment (Online Methods). For example, we found that the p-values of the schizophrenia SNPs tend to be 
much lower than the p-values of a randomly selected set of SNPs matched on allele frequency (p = 6.50×10-
71). 
Perhaps the most notable pattern that emerges from our biological analyses is that the inversions on 
chromosomes 8 and 17 are implicated consistently across all analyses. The inversion-tagging SNP on 
chromosome 8 is in LD with SNPs that have previously been found to be associated with BMI32 and 
triglycerides33 (Supplementary Table 22). We also conducted eQTL analyses in blood for the inversion 
itself and found that it is a significant cis-eQTL for 7 genes (Supplementary Table 24). As shown in 
Figure 4b, all 7 genes are positioned in close proximity to the inversion breakpoints, suggesting that the 
molecular mechanism underlying the inversion’s effect on neuroticism could involve the relocation of 
regulatory sequences. Two of the genes (MSRA, MTMR9) are known to be highly expressed in tissues and 
cell types that belong to the nervous system, and two (BLK, MFHAS1) in the immune system. In the tissue-
specific analyses, we found that the SNP tagging the inversion is a significant eQTL for two genes, 
AF131215.9 (in tibial nerve and thyroid tissue analyses) and NEIL2 (tibial nerve tissue), both of which are 
also located near the inversion breakpoint. 
The SNP tagging the chromosome 17 inversion is a significant cis-eQTL for five genes in blood and is an 
eQTL in all 14 other tissues (Supplementary Table 24). It alone accounts for 151 out of the 169 significant 
associations identified in the 14 tissue-specific analyses. Additionally, the SNP is in near-perfect LD (R2 > 
0.97) with 11 missense variants (Supplementary Table 23) in three different genes, one of which is MAPT. 
MAPT, which is also implicated in both the blood and the other tissue-specific analyses, encodes a protein 
important in the stabilization of microtubules in neurons. Associations have been previously reported 
between SNPs in MAPT (all of which are in strong LD with our inversion-tagging SNP) and 
neurodegenerative disorders, including Parkinson’s disease34 and progressive supranuclear palsy35, a rare 
disease whose symptoms include depression and apathy. 
DISCUSSION 
The discovery of genetic loci associated with SWB, depression, and neuroticism has proven elusive. Our 
study identified several credible associations for two main reasons. First, our analyses had greater statistical 
power than prior studies because ours were conducted in larger samples. Our GWAS findings—three loci 
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associated with SWB, two with DS, and eleven with neuroticism—support the view that GWAS can 
successfully identify genetic associations with highly polygenic phenotypes in sufficiently large samples5,36. 
A striking finding is that two of our identified associations are with inversion polymorphisms. 
Second, our proxy-phenotype analyses further boosted power by exploiting the strong genetic overlap 
between our three phenotypes. These analyses identified two additional loci associated with neuroticism and 
two with both DS and neuroticism. Through our quasi-replication tests, we also demonstrated how studying 
genetically overlapping phenotypes in concert can provide evidence on the credibility of GWAS findings. 
Our direct replication of the two genome-wide significant associations with DS in an independent depression 
sample provides further confirmation of those findings (Fig. 2b and Supplementary Table 15). 
We were able to assemble much larger samples than prior work in part because we combined data across 
heterogeneous phenotype measures. Our results reinforce the conclusions from our theoretical analysis that 
doing so increased our statistical power, but our strategy also has drawbacks. One is that mixing different 
measures may make any discovered associations more difficult to interpret. For example, since our DS 
phenotype is coarse and composed of varied measures, it is not clear which depressive symptoms are 
responsible for the genetic associations we found. Research studying higher quality measures of the various 
facets of SWB, DS, and neuroticism is a critical next step. Our results can help facilitate such work because 
if the variants we identify are used as candidates, studies conducted in the smaller samples in which more 
fine-grained phenotype measures are available can be well powered. 
Another limitation of mixing different measures is that doing so may reduce the heritability of the resulting 
phenotype, if the measures are influenced by different genetic factors. Indeed, our estimates of SNP-based 
heritability10 for our three phenotypes are quite low: 0.040 (SE = 0.002) for SWB, 0.047 (SE = 0.004) for 
DS, and 0.091 (SE = 0.007) for neuroticism. We correspondingly find that polygenic scores constructed 
from all measured SNPs explain a low fraction of variance in independent samples: ~0.9% for SWB, ~0.5% 
for DS, and ~0.7% for neuroticism (Online Methods). The low heritabilities imply that even when polygenic 
scores can be estimated using much larger samples than ours, they are unlikely to attain enough predictive 
power to be clinically useful. 
According to our Bayesian calculations, the true explanatory power (corrected for winner’s curse) of the 
SNP with the largest posterior R2 is 0.003% for SWB, 0.002% for DS, and 0.011% for neuroticism 
(Supplementary Table 14). These effect sizes imply that in order to account for even a moderate share of 
the heritability, hundreds or (more likely) thousands of variants will be required. They also imply that our 
study’s power to detect variants of these effect sizes was not high—for example, our statistical power to 
detect the lead SNP with largest posterior R2 was only ~13%—which in turn means it is likely that there 
exist many variants with effect sizes comparable to our identified SNPs that evaded detection. These 
estimates suggest that many more loci will be found in studies with sample sizes realistically attainable in 
the near future. 
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Online Methods 
This article is accompanied by a Supplementary Note with details on the genome-wide association analyses 
and follow-up analyses reported in the article. 
Accession codes. Meta-analysis results can be downloaded from the SSGAC website 
(http://www.thessgac.org/#!data/kuzq8). For neuroticism and DS, meta-analysis results from the combined 
analyses are provided for all variants. For SWB, meta-analysis results for all variants are provided for the 
full sample excluding 23andMe, which is subject to special restrictions. For the full SWB meta-analysis, we 
provide results for 10,000 SNPs. 
Clumping algorithm. To identify the 16 approximately independent (“lead”) SNPs shown in Panel A of 
Table 1, we used the following clumping algorithm. First, the SNP with the smallest p-value was identified 
in the meta-analysis results. This SNP was designated the lead SNP of clump 1. Second, we identified all 
SNPs whose LD with the lead SNP exceeds R2 = 0.1 and assigned them to clump 1. To generate the second 
clump, we removed the SNPs in clump 1 and then followed the same steps: the remaining SNP with lowest 
p-value was designated the lead SNP of clump 2, and all remaining SNPs whose LD with the lead SNP 
exceeds R2 = 0.1 were assigned to clump 2. The process is repeated to identify further lead SNPs and their 
corresponding clumps until no genome-wide significant SNPs remain. The clumps define “loci” of the 
genome that are associated with the phenotype. For several of our other analyses (described below), we use 
the same clumping algorithm, albeit with lower p-value thresholds than genome-wide significance, to 
identify a set of approximately independent variants. 
GWAS of SWB. Genome-wide association analyses were performed at the cohort level according to a pre-
specified analysis plan. Genotyping was performed using a range of common, commercially available 
genotyping arrays. The analysis plan instructed cohorts to upload results imputed using the HapMap2 CEU 
(r22.b36) reference sample37. We meta-analyzed summary association statistics from 59 contributing cohorts 
with a combined sample size of 298,420 individuals. Before meta-analysis, a uniform set of quality-control 
(QC) procedures were applied to the cohort-level summary statistics, including but not limited to the 
EasyQC38 protocol. All analyses were restricted to European-ancestry individuals. 
We performed a sample-size-weighted meta-analysis of the cohort-level summary statistics in Metal39. To 
adjust standard errors for non-independence, we inflated them using the square root of the estimated 
intercept from a LD Score regression10. Although we consider them secondary to the SWB analyses, we also 
performed separate meta-analyses of PA (N = 180,281) and LS (N = 166,205) and a post hoc genome-wide 
analysis of SWB in cohorts with 1000G-imputed data (N = 229,883); see Supplementary Figures 3-4 for 
quantile-quantile and Manhattan plots, and Supplementary Figure 5 for LocusZoom of the two SNPs that 
reached genome-wide significance in the SWB analysis of 1000G-imputed data. 
Detailed cohort descriptions, information about cohort-level genotyping and imputation procedures, cohort-
level measures, and quality-control filters are shown in Supplementary Tables 2-6. Supplementary Table 
7 reports association results from the following four meta-analyses: the primary SWB analysis, the LS 
analysis, the PA analysis, and the post hoc SWB analysis. For each phenotype, we provide association 
results for the set of approximately independent SNPs that attained a p-value smaller than 10-5. We identify 
these SNP using our clumping algorithm, but with the p-value threshold set at 10-5 instead of genome-wide 
significance. 
GWAS of DS and neuroticism. Our auxiliary genome-wide association studies of DS and neuroticism were 
conducted in 1000G-imputed data, combining new genome-wide association analyses with publicly 
available summary statistics from previously published studies. We applied a similar QC protocol to that 
used in our primary SWB analysis. In the DS meta-analysis (N = 180,866), we weighted the UKB analysis 
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by sample size and the two case-control studies by effective sample size39. In the neuroticism meta-analysis, 
we performed a sample-size-weighted fixed-effects meta-analysis of the UKB data and the publicly 
available summary statistics from a previous GWAS of neuroticism.  
Detailed cohort descriptions, information about cohort-level genotyping and imputation procedures and 
quality-control filters are provided in Supplementary Tables 8-12. See Supplementary Figure 6 for 
quantile-quantile plots of the neuroticism and DS meta-analysis results. Association results for the set of 
approximately independent set of SNPs that attained a p-value smaller than 10-5 are supplied in 
Supplementary Table 25. 
Two of our lead SNPs on chromosome 18 (rs1557341 and rs12961969) reached genome-wide significance 
in unconditional analyses, and their pairwise linkage disequilibrium is below our cutoff of R2 = 0.10. They 
therefore satisfy our definition of approximate independence. We found in additional robustness analyses 
that the evidence that that these SNPs reflect independent genetic signals is weaker than for the remaining 
SNPs identified in our main analysis (Supplementary Note). 
Population stratification. To quantify the fraction of the observed inflation of the mean test statistic that is 
due to bias, we used LD Score regression10. The estimated LD Score regression intercepts were all close to 
1, suggesting no appreciable inflation of the test statistics attributable to population stratification in any of 
our SWB, DS, or neuroticism meta-analyses (Supplementary Fig. 7). For all three phenotypes, our 
estimates suggest that less than 2% of the observed inflation of the mean test statistic was accounted for by 
bias. 
In our primary GWAS of SWB, we also used two family-based analyses to test for and quantify 
stratification biases. These analyses used within-family (WF) estimates, the coefficients from regressing the 
difference in phenotype across siblings on the difference in siblings’ genotype (and controls). These WF 
estimates are not biased by population stratification because siblings share their ancestry entirely, and 
therefore differences in siblings’ genotypes cannot be due to the siblings being from different population 
groups. We meta-analyzed association statistics from WF analyses conducted in four cohorts. 
In the first analysis, we estimated the fraction of SNPs for which the signs of the WF estimates were 
concordant with the signs of the estimates obtained from a GWAS identical to our primary SWB GWAS 
except with the four family cohorts excluded. For the 112,884 approximately independent SNPs considered, 
we found a sign concordance of 50.83%, which is significantly greater than 50% (p = 1.04 × 10-8). Under the 
null hypothesis of no population stratification, the observed sign concordance matches the expected rate 
after winner’s curse adjustment nearly perfectly, 50.83%. 
The second analysis utilized the WF regression coefficient estimates (i.e., not only their signs) to estimate 
the amount of stratification bias. For each SNP ݆, let ߚመ௝ denote the GWAS estimate, and let ߚመௐி,௝ denote the 
WF estimate. Under the assumption that the causal effect of each SNP is the same within families as in the 
population, we can decompose the estimates as: 
ߚመ௝ ൌ ߚ௝ ൅ ݏ௝ ൅ ௝ܷ	
ߚመௐி,௝ ൌ ߚ௝ ൅ ௝ܸ, 
where ߚ௝ is the true underlying GWAS parameter for SNP ݆, ݏ௝ is the bias due to stratification (defined to be 
orthogonal to ߚ௝ and ௝ܷ), and ௝ܷ and ௝ܸ are the sampling variances of the estimates with Eሺ ௝ܷሻ ൌ Eሺ ௝ܸሻ ൌ 0. 
Since stratification biases are absent in WF analyses, the second equation does not have a bias term. 
Whenever ݏ௝ ്	0, the GWAS estimate of ߚመ௝	is biased away from the population parameter ߚ௝. The 
proportion of variance in the GWAS coefficients accounted for by true genetic signals can be written as: 
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Varሺߚ௝ሻ
Var൫ߚ௝൯ ൅ Varሺݏ௝ሻ. 
In Supplementary Note, we show that with estimates of ߚመ௝ and ߚመௐி,௝ (and their standard errors) from 
independent samples, it is possible to consistently estimate the above ratio. We found that with 95% 
confidence, between 72% and 100% of the signal in GWAS estimates is a result of true genetic effects on 
SWB rather than stratification. 
Analyses of inversion polymorphisms. Two genome-wide significant SNPs for the neuroticism analysis 
are located within well-known inversion polymorphisms, on chromosomes 8 and 17. Using the genotypic 
data available for UKB participants, we called the inversion genotypes for UKB participants using a PCA-
mixture method. For both inversions, the method clearly distinguishes 3 clusters of genotypes, 
corresponding to inversion genotypes (Supplementary Fig. 8). We validated the PCA-mixture procedure 
using existing methods designed to call inversion genotypes40 (Supplementary Table 26). 
For both inversions, we established that the inversion-tagging SNPs were always located in close proximity 
of the inversion region (Fig. 3b and Supplementary Figs. 8-9). Supplementary Tables 27-28 list the 
twenty variants that most strongly correlate with the PCs that capture the inversion polymorphisms on 
chromosome 8 and 17, respectively. In additional analyses, we confirmed that the inversion is associated 
with neuroticism and SWB in independent cohorts (Supplementary Tables 29-30 and Supplementary Fig. 
10). 
Proxy-phenotype analyses. In these analyses, we used a two-stage approach that has been successfully 
applied in other contexts6. In the first stage, we conducted a meta-analysis of our first-stage “proxy 
phenotype” and used our clumping procedure to identify the set of approximately independent SNPs at the 
p-value threshold of 10-4. In the second stage, we tested SNPs identified in stage 1 (or high-LD proxies for 
them) for association with a second-stage phenotype in an independent (non-overlapping) sample. In our 
analyses, we used our primary phenotype of SWB as the proxy-phenotype. We conducted one analysis with 
DS as the second-stage phenotype, and one analysis with neuroticism as the second-stage phenotype. In the 
analyses, we omit cohorts from the first-stage or second-stage as needed to ensure that the samples in the 
two stages are non-overlapping. Supplementary Table 31 lists the cohort restrictions imposed. These 
cohort restrictions, as well as the p-value threshold of 10-4, were chosen before the data were analyzed on the 
basis of statistical power calculations. 
To test for cross-phenotype enrichment, we used a non-parametric procedure that tests whether the lead 
SNPs are more strongly associated with the second-stage phenotype than randomly chosen sets of SNPs 
with a similar distribution of allele frequencies. We generated 1,000 matched SNPs for each of the Y 
lead/lead-proxy SNPs. We then ranked the Y×1000 + Y SNPs by p-value and conducted a Mann-Whitney 
test41 of the null hypothesis that the p-value distribution of the Y lead/lead-proxy SNPs are drawn from the 
same distribution as the Y×1000 matched SNPs. 
To test the individual lead SNPs for experiment-wide significance, we examined whether any of the lead 
SNPs (or their high-LD proxies) are significantly associated with the second-stage phenotype at the 
Bonferroni-adjusted significance level of 0.05/Y. 
Genetic correlations. We used bivariate LD Score regression10 to quantify the amount of genetic 
heterogeneity among the phenotypic measures pooled in each of our three separate meta-analyses. For SWB, 
we estimated a pairwise correlation of 0.981 (SE = 0.065) between LS and PA, 0.897 (SE = 0.017) between 
“WB” (our measure that combines LS and PA) and LS, and 1.031 (SE = 0.019) between PA and WB. For 
DS, we estimated a genetic correlation of 0.588 (SE = 0.242) between GERA and PGC, 0.972 (SE = 0.216) 
between GERA and UKB, and 0.797 (SE = 0.108) between UKB and PGC. Finally, we estimated a genetic 
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correlation of 1.11 (SE = 0.14) between the measures of neuroticism in the UKB analyses and the summary 
statistics from a previously published meta-analysis4. 
Using the same method, we estimated the pairwise genetic correlations between our three phenotypes of 
SWB, DS, and neuroticism and between each of our three phenotypes and the ten neuropsychiatric and 
physical health variables (for which publicly available summary statistics were available). 
Bayesian credibility analyses. To evaluate the credibility of our findings, we use a standard Bayesian 
framework19 in which our prior distribution for any SNP’s effect is: 
ߚ~ ൜ܰ൫0, ௝߬ଶ൯ with	probability	ߨ0 otherwise. . 
Here, ߨ is the fraction of non-null SNPs, and ௝߬ଶ is the variance of the non-null SNPs for trait j ∈ {SWB, DS, 
neuroticism}. In this framework, credibility is defined as the probability that a given SNP is non-null. 
We begin with univariate analyses of the GWAS results that do not incorporate the additional information 
from the quasi-replication analyses of the 16 lead SNPs reported in Table 1. We use the three SWB-
associated SNPs to illustrate our approach, but we use analogous procedures when analyzing DS and 
neuroticism. We calculate credibility for each value ߨ ∈ ሼ0.01,0.02, … ,0.99ሽ. For each assumed value of ߨ, 
we estimate ߬ௌௐ஻ଶ  by maximum likelihood (Supplementary Note). For each SNP, we use Bayes’ rule to 
obtain a posterior estimate of credibility for each of the assumed values of ߨ. Supplementary Figure 12 
shows that for all considered values of ߨ and all three SNPs, the posterior probability that the SNP is null is 
below 1%. Similar analyses of the DS and neuroticism SNPs show that the posterior probability never 
exceeds 5%. 
In our joint analyses, we consider two phenotypes with genetic correlation ݎ௚. We make the simplifying 
assumption that the set of null SNPs is the same for both phenotypes. The joint distribution of a SNP’s effect 
on the two phenotypes is then given by 
൤ߚଵߚଶ൨~
ە
۔
ۓܰ ቆቂ00ቃ , ቈ
߬ଵଶ ߬ଵ߬ଶݎ௚
߬ଵ߬ଶݎ௚ ߬ଶଶ ቉ቇ with	probability	ߨ
ቂ00ቃ otherwise.
 
With coefficient estimates, ߚመଵ and ߚመଶ, obtained from non-overlapping samples, the variance-covariance 
matrix of the estimation error will be diagonal. We denote the diagonal entries of this matrix, which 
represent the variances of the estimation error in the two samples, by ߪଵଶ and ߪଶଶ. This gives us the joint prior 
distribution 
ቈߚመଵߚመଶ቉ ~
ۖە
۔
ۖۓܰ ቆቂ00ቃ , ቈ
߬ଵଶ ߬ଵ߬ଶݎ௚
߬ଵ߬ଶݎ௚ ߬ଶଶ ቉ ൅ ൤
ߪ12 0
0 σ22൨ቇ with	probability	ߨ
ܰ ൬ቂ00ቃ , ൤
ߪ12 0
0 σ22൨൰ . otherwise.
 
To select parameter values for the prior, we use the estimates of ݎ௚ reported in Supplementary Table 1, and 
we estimate the parameters ߨ, ߬ଵଶ, and ߬ଶଶ from GWAS summary statistics using a maximum likelihood 
procedure. For this procedure, we make the standard assumption10,42 that the variance of a SNP’s effect size 
is inversely proportional to the variance of its genotype, 2 ൈ MAF ൈ ሺ1 െ MAFሻ. (This assumption implies 
that rare SNPs are more likely to have large effects.)  
The credibility estimates follow from applying Bayes’ Rule to calculate either the probability that the SNP is 
non-null (an event denoted ܥ) given only the first-stage estimate, ܲ൫ܥ	|	ߚመଵ൯, or the probability that the SNP 
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is non-null conditional on the results of both the first-stage GWAS and the quasi-replication analysis, 
ܲ൫ܥ	|	ߚመଵ, ߚመଶ൯. Credibility estimates for our lead SNPs are in Supplementary Table 14. 
To calculate the expected record of a replication or quasi-replication study, we assume that the SNP is non-
null for both phenotypes. (This is analogous to a standard power calculation for a single phenotype, in which 
the SNP is assumed to be non-null.) Under this assumption, ߚመଵ and ߚመଶ are jointly normally distributed, 
implying that the conditional distribution of ߚመଶ given ߚመଵ is 
൫ߚመଶ	|	ߚመଵ, ܥ൯~ܰ ቈ ߬ଵ߬ଶݎ௚߬ଵଶ ൅ ߪଵଶ ߚ
መଵ,
ሺ߬ଵଶ ൅ ߪଵଶሻሺ߬ଶଶ ൅ ߪଶଶሻ െ ߬ଵଶτଶଶݎ௚ଶ
߬ଵଶ ൅ ߪଵଶ ቉. 
Using this equation, we can calculate the probability that the GWAS estimates will have concordant signs 
across the two phenotypes, or that the GWAS estimate of the second-stage phenotype will reach some level 
of significance (or other measures of replicability). These probabilities can be summed over the set of lead 
SNPs to generate the expected number of SNPs meeting the criterion. 
To obtain effect-size estimates for a SNP that are adjusted for the winner’s curse (Supplementary Table 
32), we use the mean of the posterior distribution of the SNP’s effect, conditional on the quasi-replication 
result and the SNP being non-null. The posterior distribution is 
൫ߚଵ	|	ߚመଵ, ߚመଶ, ܥ൯~ܰൣ݉൫ߚመଵ, ߚመଶ൯, ݏ൫ߚመଵ, ߚመଶ൯൧ 
where, 
݉൫ߚመଵ, ߚመଶ൯ ≡ ቆ ߬ଵ
ଶሺ߬ଶଶ ൅ ߪଶଶሻ െ ݎ௚ଶ߬ଵଶ߬ଶଶ
ሺ߬ଵଶ ൅ ߪଵଶሻሺ߬ଶଶ ൅ ߪଶଶሻ െ ݎ௚ଶ߬ଵଶ߬ଶଶቇߚ
መଵ ൅ ቆ ݎ௚߬ଵ߬ଶߪଵ
ଶ
ሺ߬ଵଶ ൅ ߪଵଶሻሺ߬ଶଶ ൅ ߪଶଶሻ െ ݎ௚ଶ߬ଵଶ߬ଶଶቇߚ
መଶ	
ݏ൫ߚመଵ, ߚመଶ൯ ≡ ߬ଵ
ଶߪଵଶ൫߬ଶଶ ൅ ߪଶଶ െ ݎ௚ଶ߬ଶଶ൯
ሺ߬ଵଶ ൅ ߪଵଶሻሺ߬ଶଶ ൅ ߪଶଶሻ െ ݎ௚ଶ߬ଵଶ߬ଶଶ. 
The winner’s-curse-adjusted GWAS coefficient is simply the mean of the posterior distribution. The 
expected ܴଶ of the SNP for the first-stage phenotype is 
 ܧ൫ܴଵଶ	|	ߚመଵ, ߚመଶ൯ ൌ ቂ݉൫ߚመଵ, ߚመଶ൯ଶ ൅ ݏ൫ߚመଵ, ߚመଶ൯ቃ ߪ௫ଶܲ൫ܥ	|	ߚመଵ, 	ߚመଶ൯,  
where ߪ௫ଶ ൌ 2	 ൈ MAF ൈ ሺ1 െ MAFሻ is the variance of the genotype under Hardy-Weinberg equilibrium. 
The winner’s curse adjusted formulas for the second-stage phenotype are symmetric.  
Lookup of DS and neuroticism-associated SNPs in an independent depression study. We partnered with 
the investigators of an ongoing large-scale GWAS of major depressive symptoms (N = 368,890) to follow 
up on the associations identified in the DS and neuroticism analyses (and reciprocally supplied them with 
association results for their most significant associations). The participants of the study were all European-
ancestry customers of 23andMe, a personal genomics company, who responded to online survey questions 
about mental health. We did not request results for the SNPs identified in the SWB or proxy-phenotype 
analyses, since these were both conducted in samples that overlap with 23andMe’s depression sample. For 
details on association models, quality-control filters, and the ascertainment of depression status, we refer to 
the companion study21. The p-values we report are based on standard errors that have been inflated by the 
square by the intercept from an LD score regression10.  
Polygenic prediction. To evaluate the predictive power of a polygenic score derived from the SWB meta-
analysis results, we used two independent hold-out cohorts: the Health and Retirement Study (HRS43) and 
the Netherlands Twin Register (NTR44,45). To generate the weights for the polygenic score, we performed 
meta-analyses of the pooled SWB phenotype excluding each of the holdout cohorts, applying a minimum-
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sample-size filter of 100,000 individuals. Using the summary statistics from this meta-analysis, we 
constructed two sets of polygenic scores: (1) LDpred polygenic scores, with weights constructed from 
conditional SNP effects estimated from summary statistics using information about LD structure from a 
reference sample20, and (2) linear polygenic scores using the unconditional GWAS effect sizes46. We 
examined the predictive power of the score for the following outcomes: SWB, LS, PA, depression, the NEO 
Big Five personality traits47, and height (the last being included as a negative control). The results from 
these analyses are reported in Supplementary Table 32 and depicted in Supplementary Figure 13. 
Enrichment of schizophrenia SNPs for association with neuroticism. In post hoc analyses, we used the 
test of cross-phenotype enrichment described in the “Proxy-phenotype analysis” Online Methods section to 
examine whether the genome-wide associations that have been reported for schizophrenia showed evidence 
for enriched association with neuroticism in a non-overlapping sample. Among our phenotypes, we focused 
on neuroticism to maximize power. 
For the schizophrenia SNPs (128 of them31), we strongly reject the null hypothesis of no enrichment relative 
to a set of SNPs matched on allele frequency (p = 6.50ൈ 10ି଻ଵ). Also, 23 of the 106 matched schizophrenia 
SNPs are nominally significantly associated (p-value < 0.05) with neuroticism in our sample, and 19 of these 
23 SNPs have concordant signs for schizophrenia and neuroticism. For bipolar disease SNPs (five of them48) 
and anxiety disorder (two SNPs49), we found no evidence of enrichment. 
Biological annotation. For each of SWB, DS, and neuroticism, we used stratified LD score regression26 to 
test for enriched association with SNPs in (i) functional genomic regions of the genome and (i) SNPs located 
near histone marks in specific tissues. 
For the biological annotation of the 20 SNPs in Table 1, we generated a list of LD partners for each of the 
original SNPs. A SNP was considered an LD partner for the original SNP if (i) its pairwise LD with the 
original SNP exceeded R2 = 0.6 and (ii) it was located within 250kb of the original SNP. We also generated 
a list of genes residing within loci tagged by our lead SNPs (Supplementary Table 34). 
We used the NHGRI GWAS catalog50 to determine which of our 20 SNPs (and their LD partners) were in 
LD with SNPs for which genome-wide significant associations have been previously reported. Since the 
GWAS catalog does not always include the most recent GWAS results available, we included additional 
recent GWAS studies. We used the tool HaploReg51 to identify nonsynonymous variants in LD with any of 
the 20 SNPs or their LD partners. 
We examined whether the 20 polymorphisms in Table 1 were associated with gene expression levels 
(Supplementary Table 24). The cis-eQTL associations were performed in 4,896 peripheral-blood gene 
expression and genome-wide SNP samples from two Dutch cohorts measured on the Affymetrix U219 
platform44,45,52. We considered a SNP a potential cis-eQTL if the distance between the SNP and the midpoint 
of the probe set was smaller than 1Mb. The cis-eQTL analyses of the inversion were conducted separately. 
To supplement the analyses in blood, we performed eQTL lookups of our 20 SNPs in the Genotype-Tissue 
Expression Portal (www.GTExportal.org)53,54. For a given SNP, the portal provides results in various tissues 
for tests of association between the SNP and gene expression of genes whose transcription start site is within 
one Mb of the SNP. We restricted the search to the following trait-relevant tissues: hippocampus, 
hypothalamus, anterior cingulate cortex (BA24), putamen (basal ganglia), frontal cortex (BA9), nucleus 
accumbens (basal ganglia), caudate (basal ganglia), cortex, cerebellar hemisphere, cerebellum, tibial nerve, 
thyroid, adrenal gland, and pituitary. 
Finally, using a gene co-expression database55, we explored the predicted functions of genes co-locating 
with the 20 SNPs in Table 1 (Supplementary Table 35).  
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Fig. 1. Manhattan plots. (a) Subjective well-being (N = 298,420), (b) Depressive symptoms (N = 180,866), (c) Neuroticism (N = 170,911). The x-axis is 
chromosomal position, and the y-axis is the significance on a −logଵ଴ scale. The upper dashed line marks the threshold for genome-wide significance (p = 5×10-
8); the lower line marks the threshold for nominal significance (p = 10-5). Each approximately independent genome-wide significant association (“lead SNP”) is 
marked by ×. Each lead SNP is the lowest p-value SNP within the locus, as defined by our clumping algorithm (Online Methods).  
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Fig. 2. Genetic correlations. The correlations are estimated using bivariate LD Score 
(LDSC) regression. (a) Genetic correlations between SWB, DS, and neuroticism (“our three 
phenotypes”), as well as between our three phenotypes and height. (b) Genetic correlations 
between our three phenotypes and selected neuropsychiatric phenotypes. (c) Genetic 
correlations between our three phenotypes and selected physical health phenotypes. In (b) 
and (c), we report the negative of the estimated correlation with DS and neuroticism (but not 
SWB). 
 
a 
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Fig. 3. Quasi-replication and lookup of lead SNPs. In quasi-replication analyses, we examined whether (a) lead SNPs identified in the SWB meta-analyses 
are associated with DS or neuroticism, (b) lead SNPs identified in the analyses of DS are associated with SWB, and (c) lead SNPs identified in the analyses of 
neuroticism are associated with SWB. The quasi-replication sample is always restricted to non-overlapping cohorts. In a separate lookup exercise, we examined 
whether lead SNPs for DS and neuroticism are associated with depression in an independent sample of 23andMe customers (N = 368,890). The results from 
this lookup are depicted as green crosses in (b) and (c). Bars represent 95% CIs (not adjusted for multiple testing). For interpretational ease, we choose the 
reference allele so that positive coefficients imply that the estimated effect is in the predicted direction. Listed below each lead SNP is the nearest gene. 
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Fig. 4. Results from selected biological analyses. (a) Estimates of the expected increase in 
the phenotypic variance accounted for by a SNP due to the SNP’s being in a given category 
(߬௖), divided by the LD Score heritability of the phenotype (݄ଶ). Each estimate of ߬௖ comes 
from a separate stratified LD Score regression, controlling for the 52 functional annotation 
categories in the “baseline model.” The bars represent 95% CIs (not adjusted for multiple 
testing). To benchmark the estimates, we compare them to those obtained from a recent study 
of height27. (b) Inversion polymorphism on chromosome 8 and the 7 genes for which the 
inversion is a significant cis-eQTL at FDR < 0.05. The upper half of the figure shows the 
Manhattan plot for neuroticism for the inversion and surrounding regions. The bottom half 
shows the squared correlation between the SNPs and the principal component that captures 
the inversion. The inlay plots the relationship, for each SNP in the inversion region, between 
the SNP’s significance and its squared correlation with the principal component that captures 
the inversion. 
a 
 
b 
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Table 1. Summary of polymorphisms identified across analyses. EA: effect allele. EAF: effect 
allele frequency. All effect sizes are reported in units of SDs per allele. “Quasi-Repl.”: 
phenotypes for which SNP was found to be nominally associated in quasi-replication analyses 
conducted in independent samples. *significant at the 5%-level, **significant at the 1%-level, 
***significant at the 0.1%-level.  #inversion-tagging polymorphism on chromosome 8. 
##inversion-tagging polymorphism on chromosome 17.  †proxy for rs6904596 (R2 = 0.98). 
 
Panel A. Genome-Wide Significant Associations 
Subjective Well-Being (SWB, N = 298,420) 
SNPID CHR BP EA EAF Beta SE R2 p-value  N Quasi-Repl 
rs3756290 5 130,951,750 A 0.24 -0.0177 0.0031 0.011% 9.6×10-9 286,851 
rs2075677 20 47,701,024 A 0.76 0.0175 0.0031 0.011% 1.5×10-8 288,454 DS** 
rs4958581 5 152,187,729 T 0.66 0.0153 0.0027 0.011% 2.3×10-8 294,043 DS*** 
Neuroticism (N = 170,908) 
SNPID CHR BP EA EAF Beta SE R2 p-value  N Quasi-Repl 
rs2572431#  8 11,105,077 T 0.41 0.0283 0.0035 0.039% 4.2×10-16 170,908 SWB* 
rs193236081##  17 44,142,332 T 0.77 -0.0284 0.0045 0.028% 6.3×10-11 151,297 
rs10960103 9 11,699,270 C 0.77 0.0264 0.0038 0.024% 2.1×10-10 165,380 ܦଶଷ௔௡ௗெ௘∗  
rs4938021 11 113,364,803 T 0.34 0.0233 0.0037 0.024% 4.0×10-10 159,900 ܦଶଷ௔௡ௗெ௘∗∗∗ , SWB* 
rs139237746 11 10,253,183 T 0.51 -0.0204 0.0034 0.021% 2.6×10-9 170,908 
rs1557341 18 35,127,427 A 0.34 0.0213 0.0036 0.021% 5.6×10-9 165,579 ܦଶଷ௔௡ௗெ௘∗∗  
rs12938775 17 2,574,821 A 0.47 -0.0202 0.0035 0.020% 8.5×10-9 163,283 SWB* 
rs12961969 18 35,364,098 A 0.2 0.0250 0.0045 0.020% 2.2×10-8 156,758 
rs35688236 3 34,582,993 A 0.69 0.0213 0.0037 0.019% 2.4×10-8 161,636 
rs2150462 9 23,316,330 C 0.26 -0.0217 0.0038 0.018% 2.7×10-8 170,907 
rs12903563 15 78,033,735 T 0.50 0.0198 0.0036 0.020% 2.9×10-8 157,562 ܦଶଷ௔௡ௗெ௘∗ ,SWB* 
Depressive Symptoms (DS, N = 180,866) 
SNPID CHR BP EA EAF Beta SE R2 p-value  N Quasi-Repl/Repl 
rs7973260 12 118,375,486 A 0.19 0.0306 0.0051 0.029% 1.8×10-9 124,498 ܦଶଷ௔௡ௗெ௘∗  
rs62100776 18 50,754,633 A 0.56 -0.0252 0.0044 0.031% 8.5×10-9 105,739 ܦଶଷ௔௡ௗெ௘∗∗ ,SWB* 
Panel B.  SNPs Identified via Proxy-Phenotype Analyses of SWB Loci with p-value<10-4 
Depressive Symptoms in Non-Overlapping Cohorts 
SNPID CHR BP EA EAF BetaDS SEDS R2 pDS Bonferroni NDS 
rs4346787† 6 27,491,299 A 0.113 -0.023 0.0059 0.011% 9.8×10-5 0.0160 142,265 
rs4481363 5 164,483,794 A 0.524 0.014 0.0038 0.009% 3.1×10-4 0.0499 142,265 
Neuroticism in Non-Overlapping Cohorts 
SNPID CHR BP EA EAF Betaneuro SEneuro R2 pneuro Bonferroni Nneuro 
rs10838738 11 47,663,049 A 0.49 0.0178 0.0039 0.016% 5.0×10-6 0.0009 131,864 
rs10774909 12 117,674,129 C 0.52 -0.0150 0.0039 0.011% 1.2×10-4 0.0203 131,235 
rs6904596 6 27,491,299 A 0.09 -0.0264 0.0072 0.012% 2.5×10-4 0.0423 116,335 
rs4481363 5 164,474,719 A 0.49 0.0151 0.0040 0.011% 1.9×10-4 0.0316 122,592 
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